Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group.
Rosenbrock J, Kaul H, Oertel M, Celik E, Linde P, Fan J, Eichenauer DA, Bröckelmann PJ, von Tresckow B, Kobe C, Dietlein M, Fuchs M, Borchmann P, Eich HT, Baues C. Rosenbrock J, et al. Among authors: borchmann p. Int J Radiat Oncol Biol Phys. 2024 Apr 15:S0360-3016(24)00514-5. doi: 10.1016/j.ijrobp.2024.04.015. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38631539 Free article.
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A. Borchmann P, et al. Lancet Oncol. 2021 Feb;22(2):223-234. doi: 10.1016/S1470-2045(20)30601-X. Lancet Oncol. 2021. PMID: 33539742 Clinical Trial.
Involved Site Radiotherapy Extends Time to Premature Menopause in Infra-Diaphragmatic Female Hodgkin Lymphoma Patients - An Analysis of GHSG HD14- and HD17-Patients.
Rosenbrock J, Vásquez-Torres A, Mueller H, Behringer K, Zerth M, Celik E, Fan J, Trommer M, Linde P, Fuchs M, Borchmann P, Engert A, Marnitz S, Baues C. Rosenbrock J, et al. Among authors: borchmann p. Front Oncol. 2021 May 25;11:658358. doi: 10.3389/fonc.2021.658358. eCollection 2021. Front Oncol. 2021. PMID: 34113567 Free PMC article.
Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial.
Baues C, Goergen H, Fuchs M, Rosenbrock J, Celik E, Eich H, Kobe C, Voltin CA, Engert A, Borchmann P, Marnitz S. Baues C, et al. Among authors: borchmann p. Int J Radiat Oncol Biol Phys. 2021 Nov 15;111(4):900-906. doi: 10.1016/j.ijrobp.2021.07.1697. Epub 2021 Aug 11. Int J Radiat Oncol Biol Phys. 2021. PMID: 34389407 Clinical Trial.
Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era.
Oertel M, Hering D, Nacke N, Kittel C, Kröger K, Kriz J, Fuchs M, Baues C, Vordermark D, Engenhart-Cabillic R, Herfarth K, Lukas P, Schmidberger H, Marnitz S, Borchmann P, Engert A, Haverkamp U, Eich HT. Oertel M, et al. Among authors: borchmann p. Adv Radiat Oncol. 2022 Dec 30;8(3):101169. doi: 10.1016/j.adro.2022.101169. eCollection 2023 May-Jun. Adv Radiat Oncol. 2022. PMID: 36896214 Free PMC article.
Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma- a risk stratified analysis of the GHSG HD17 trial.
Oertel M, Hering D, Baues C, Kittel C, Fuchs M, Kriz J, Kröger K, Vordermark D, Herfarth K, Engenhart-Cabillic R, Lukas P, Haverkamp U, Borchmann P, Eich HT. Oertel M, et al. Among authors: borchmann p. Front Oncol. 2023 May 5;13:1183906. doi: 10.3389/fonc.2023.1183906. eCollection 2023. Front Oncol. 2023. PMID: 37213291 Free PMC article.
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, Klutmann S, Knapp WH, Zijlstra JM, Bockisch A, Weckesser M, Lorenz R, Schreckenberger M, Bares R, Eich HT, Mueller RP, Fuchs M, Borchmann P, Schicha H, Diehl V, Engert A. Kobe C, et al. Among authors: borchmann p. Blood. 2008 Nov 15;112(10):3989-94. doi: 10.1182/blood-2008-06-155820. Epub 2008 Aug 29. Blood. 2008. PMID: 18757777 Free PMC article. Clinical Trial.
Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.
Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Böll B, von Tresckow B, Nogová L, Borchmann P, Engert A. Eichenauer DA, et al. Among authors: borchmann p. Blood. 2011 Oct 20;118(16):4363-5. doi: 10.1182/blood-2011-06-361055. Epub 2011 Aug 9. Blood. 2011. PMID: 21828141 Free article. Clinical Trial.
247 results